KR100583667B1 - 아리피프라졸의 제조방법 - Google Patents
아리피프라졸의 제조방법 Download PDFInfo
- Publication number
- KR100583667B1 KR100583667B1 KR1020047003990A KR20047003990A KR100583667B1 KR 100583667 B1 KR100583667 B1 KR 100583667B1 KR 1020047003990 A KR1020047003990 A KR 1020047003990A KR 20047003990 A KR20047003990 A KR 20047003990A KR 100583667 B1 KR100583667 B1 KR 100583667B1
- Authority
- KR
- South Korea
- Prior art keywords
- general formula
- compound represented
- carbostyryl
- group
- alkali metal
- Prior art date
Links
- 0 *c1cc(NC(CC2)=O)c2cc1 Chemical compound *c1cc(NC(CC2)=O)c2cc1 0.000 description 1
- WLHOVCQZTZDBFS-UHFFFAOYSA-N CN(CC1)CCN1c1cccc(Cl)c1Cl Chemical compound CN(CC1)CCN1c1cccc(Cl)c1Cl WLHOVCQZTZDBFS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
Abstract
Description
Claims (15)
- 제 1 항에 있어서, 1 종의 무기 염기성 화합물만을 사용하며, 상기 무기 염기성 화합물이 알칼리 금속의 수산화물, 알칼리 금속의 탄산염 또는 알칼리 금속인, 아리피프라졸의 제조방법.
- 제 1 항에 있어서, 2 종 이상의 무기 염기성 화합물을 혼합물로서 사용하며, 상기 무기 염기성 화합물의 혼합물이 알칼리 금속의 수산화물 및 알칼리 금속의 탄산염의 혼합물인, 아리피프라졸의 제조방법.
- 제 2 항 또는 제 3 항에 있어서, X 가 할로겐 원자인, 아리피프라졸의 제조방법.
- 제 2 항에 있어서, X 가 염소 원자이고, 상기 무기 염기성 화합물이 알칼리 금속의 탄산염인, 아리피프라졸의 제조방법.
- 제 3 항에 있어서, X 가 염소 원자인, 아리피프라졸의 제조방법.
- 제 2 항 또는 제 3 항에 있어서, 상기 알칼리 금속의 수산화물이 수산화 나트륨, 수산화 칼륨, 수산화 세슘 또는 수산화 리튬인, 아리피프라졸의 제조방법.
- 제 2 항, 제 3 항 및 제 5 항 중 어느 한 항에 있어서, 상기 알칼리 금속의 탄산염이 탄산 나트륨, 탄산 칼륨, 탄산 세슘, 탄산 리튬, 탄산수소 리튬, 탄산수소 나트륨 또는 탄산수소 칼륨인, 아리피프라졸의 제조방법.
- 제 2 항에 있어서, 상기 알칼리 금속이 나트륨 또는 칼륨인, 아리피프라졸의 제조방법.
- 제 1 항에 있어서, X 가 불소 원자, 염소 원자, 브롬 원자 또는 요오드 원자인, 아리피프라졸의 제조방법.
- 제 1 항에 있어서, 일반식 (3) 으로 표시되는 피페라진 화합물의 염이 히드로클로리드, 술페이트, 포스페이트, 히드로브로미드, 옥살레이트, 말레에이트, 푸마레이트, 말레이트, 타르트레이트, 시트레이트 또는 벤조에이트인, 아리피프라졸의 제조방법.
- 제 1 항에 있어서, 일반식 (3) 으로 표시되는 피페라진 화합물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 몰 당 1 내지 1.5 몰인, 아리피프라졸의 제조방법.
- 제 1 항에 있어서, 물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 중량부 당 3 내지 50 중량부이며; 일반식 (3) 으로 표시되는 피페라진 화합물의 양이 일반식 (2) 로 표시되는 카르보스티릴 화합물의 1 몰 당 1 내지 1.5 몰이며; 및 반응이 실온 내지 200 ℃ 의 범위의 온도에서 1 내지 10 시간 내에 수행되는, 아리피프라졸의 제조방법.
- 제 13 항에 있어서, 무기 염기성 화합물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 몰 당 0.5 내지 6 몰이며; 물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 중량부 당 5 내지 15 중량부이며; 일반식 (3) 으로 표시되는 피페라진 화합물의 양이 일반식 (2) 로 표시되는 카르보스티릴 화합물의 1 몰 당 1 내지 1.5 몰이며; 및 반응이 80 ℃ 내지 150 ℃ 의 범위의 온도에서 1 내지 10 시간 내에 수행되는, 아리피프라졸의 제조방법.
- 제 14 항에 있어서, 무기 염기성 화합물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 몰 당 1.1 몰이며; 물의 양이 일반식 (2) 으로 표시되는 카르보스티릴 화합물의 1 중량부 당 10 중량부이며; 일반식 (3) 으로 표시되는 피페라진 화합물의 양이 일반식 (2) 로 표시되는 카르보스티릴 화합물의 1 몰 당 1.1 몰이며; 및 반응이 90 ℃ 내지 95 ℃ 의 범위의 온도에서 4 시간 내에 수행되는, 아리피프라졸의 제조방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2003-00002996 | 2003-01-09 | ||
JP2003002996 | 2003-01-09 | ||
PCT/JP2003/016256 WO2004063162A1 (en) | 2003-01-09 | 2003-12-18 | Process for preparing aripiprazole |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040093655A KR20040093655A (ko) | 2004-11-06 |
KR100583667B1 true KR100583667B1 (ko) | 2006-05-26 |
Family
ID=32652780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047003990A KR100583667B1 (ko) | 2003-01-09 | 2003-12-18 | 아리피프라졸의 제조방법 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6995264B2 (ko) |
EP (1) | EP1480953B2 (ko) |
JP (2) | JP5797090B2 (ko) |
KR (1) | KR100583667B1 (ko) |
CN (1) | CN1263742C (ko) |
AR (1) | AR042702A1 (ko) |
AT (1) | ATE308524T1 (ko) |
AU (1) | AU2003288755C1 (ko) |
BR (2) | BRPI0305500B1 (ko) |
CA (2) | CA2458929C (ko) |
DE (1) | DE60302139T3 (ko) |
DK (1) | DK1480953T4 (ko) |
EG (1) | EG23557A (ko) |
ES (1) | ES2250919T5 (ko) |
HK (1) | HK1073110A1 (ko) |
MX (1) | MXPA04002519A (ko) |
MY (1) | MY129831A (ko) |
SI (1) | SI1480953T2 (ko) |
TW (1) | TWI258470B (ko) |
WO (1) | WO2004063162A1 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7714129B2 (en) * | 2003-12-16 | 2010-05-11 | Teva Pharmaceutical Industries Ltd. | Methods of preparing anhydrous aripiprazole form II |
PT1613598E (pt) * | 2003-12-16 | 2012-01-13 | Teva Pharma | Métodos para preparar formas cristalinas de aripiprazol |
WO2005077904A1 (en) * | 2004-02-05 | 2005-08-25 | Teva Pharmaceutical Industries, Ltd. | Process for preparing aripiprazole |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
US7872132B2 (en) * | 2004-10-08 | 2011-01-18 | Suven Life Sciences Limited | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole |
US20060079689A1 (en) * | 2004-10-12 | 2006-04-13 | Vladimir Naddaka | Processes for preparing and purifying carbostyril compounds such as aripiprazole and 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones |
EP1812397A1 (en) * | 2004-11-18 | 2007-08-01 | Synthon B.V. | Process of making crystalline aripiprazole |
CN1303068C (zh) * | 2005-01-11 | 2007-03-07 | 中国人民解放军第二军医大学 | 一种阿立哌唑的制备方法 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
EP1919453A2 (en) * | 2005-12-22 | 2008-05-14 | Teva Pharmaceutical Industries Ltd | Processes for reducing particle size of aripiprazole |
US20070149782A1 (en) * | 2005-12-23 | 2007-06-28 | Michael Brand | Methods of preparing a crystalline form of 7-(4-chlorobutoxy)-3,4-dihydro-2(1h)-quinolinone and the use thereof in the synthesis of Aripiprazole |
US20070238876A1 (en) * | 2006-04-10 | 2007-10-11 | Neera Tewari | Process for the preparation of aripiprazole |
EP2162135A4 (en) | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS |
WO2009154993A1 (en) | 2008-05-27 | 2009-12-23 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using piperazine based antipsychotic agents |
CN101781246B (zh) * | 2009-01-15 | 2012-02-29 | 成都康弘药业集团股份有限公司 | 一种合成阿立哌唑的改进方法 |
AU2010217772B2 (en) | 2009-02-26 | 2014-10-23 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
WO2016181406A1 (en) * | 2015-05-08 | 2016-11-17 | Davuluri Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
DE3034237A1 (de) † | 1979-09-18 | 1981-04-16 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
JP4060523B2 (ja) † | 1999-11-24 | 2008-03-12 | 大塚製薬株式会社 | カルボスチリル誘導体の製造法 |
AR033485A1 (es) † | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
-
2003
- 2003-12-18 EP EP03780889A patent/EP1480953B2/en not_active Expired - Lifetime
- 2003-12-18 AT AT03780889T patent/ATE308524T1/de active
- 2003-12-18 DK DK03780889.6T patent/DK1480953T4/da active
- 2003-12-18 MX MXPA04002519A patent/MXPA04002519A/es active IP Right Grant
- 2003-12-18 TW TW092135997A patent/TWI258470B/zh not_active IP Right Cessation
- 2003-12-18 ES ES03780889T patent/ES2250919T5/es not_active Expired - Lifetime
- 2003-12-18 CA CA002458929A patent/CA2458929C/en not_active Expired - Fee Related
- 2003-12-18 WO PCT/JP2003/016256 patent/WO2004063162A1/en active IP Right Grant
- 2003-12-18 CA CA002676216A patent/CA2676216A1/en not_active Abandoned
- 2003-12-18 SI SI200330153T patent/SI1480953T2/sl unknown
- 2003-12-18 KR KR1020047003990A patent/KR100583667B1/ko active IP Right Grant
- 2003-12-18 AU AU2003288755A patent/AU2003288755C1/en not_active Ceased
- 2003-12-18 BR BRPI0305500-0A patent/BRPI0305500B1/pt unknown
- 2003-12-18 BR BR0305500-0A patent/BR0305500A/pt not_active IP Right Cessation
- 2003-12-18 DE DE60302139T patent/DE60302139T3/de not_active Expired - Lifetime
-
2004
- 2004-01-05 EG EG2004010004A patent/EG23557A/xx active
- 2004-01-05 AR ARP040100006A patent/AR042702A1/es not_active Application Discontinuation
- 2004-01-08 MY MYPI20040043A patent/MY129831A/en unknown
- 2004-01-08 US US10/752,490 patent/US6995264B2/en active Active
- 2004-01-09 CN CNB2004100020641A patent/CN1263742C/zh not_active Expired - Lifetime
-
2005
- 2005-07-11 HK HK05105804A patent/HK1073110A1/xx not_active IP Right Cessation
-
2011
- 2011-11-04 JP JP2011241871A patent/JP5797090B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-06 JP JP2014043786A patent/JP2014148511A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100583667B1 (ko) | 아리피프라졸의 제조방법 | |
JPH02191256A (ja) | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 | |
JP2005350474A (ja) | シロスタゾールの製造方法 | |
JP4060523B2 (ja) | カルボスチリル誘導体の製造法 | |
US20030045547A1 (en) | Process for producing carbostyril derivatives | |
EP1845088B1 (en) | An improved process for the preparation of aripipirazole | |
WO2008026220A1 (en) | A process for purification of 7-(4-bromobutoxy)-3,4 dihydrocarbostyril, an intermediate for manufacture of aripirazole | |
JP4902945B2 (ja) | アリピプラゾールの製造法 | |
US7825251B2 (en) | Process for producing carbostyril derivatives | |
US7399864B2 (en) | Process for producing carbostyril derivatives | |
KR100459974B1 (ko) | 카르보스티릴 유도체의 제조방법 | |
WO2014136808A1 (ja) | 細胞死抑制剤及びその製造方法 | |
JP2003055375A (ja) | 光学活性ヒドラジン化合物の製造法 | |
JPH0633255B2 (ja) | テトラヒドロキノリン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140418 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150416 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160419 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170420 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180417 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190417 Year of fee payment: 14 |